Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
3rd International Conference on Data Science and Applications, ICDSA 2022 ; 552:873-884, 2023.
Article in English | Scopus | ID: covidwho-2284512

ABSTRACT

Novel corona disease is spreading all over the world. The cases of the corona virus are increasing drastically day by day. Therefore, it is necessary to predict the cases in advance to handle the condition. Recently, machine learning comes into the picture of researchers to solve the problem in engineering. The present study is focused to the application of LSTM recurrent neural network to predict the Novel corona cases on the daily basis in India. Various RNN models are used in this study, and performance evaluation of each model is carried out using different statistical parameters such as mean absolute error (MAE), mean absolute percentage error (MAPE), route mean square error (RMSE), and coefficient of determination (r2-score) for regression problems. From the study, it is concluded that the LSTM RNN model can be utilized for the prediction of the novel corona cases. © 2023, The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

2.
European Respiratory Journal Conference: European Respiratory Society International Congress, ERS ; 60(Supplement 66), 2022.
Article in English | EMBASE | ID: covidwho-2277257

ABSTRACT

Background: Severe COVID-19 has been attributed to a hyperimmune response mediated by cytokines. The mainstay of therapy remains largely supportive along with steroids. Co-trimoxazole in addition to having antimicrobial properties has immunomodulatory and anti-inflammatory properties and could potentially improve outcomes in patients with severe COVID-19 . Hypothesis: We hypothesised that Co-trimoxazole given to patients with severe COVID-19 could prevent progression to critical illness, mortality and reduce time to recovery. Method(s): We conducted an interim analysis in our single center open-label randomised control trial, in which hospitalised patients with severe COVID-19 requiring supplemental oxygen via non-rebreathe mask between 10 -15 Litres per minute and maintaining saturations between 92-96% were assigned in a 1:1 ratio to receive either oral Cotrimoxazole in addition to standard therapy or standard therapy alone. Result(s): 111 patients were recruited into the study, of which 56 patients received Co-trimoxazole and 55 received standard therapy alone. The mean age was 50 years in the Co-trimoxazole group versus 53 years in the standard therapy group (p=0.083). In-hospital mortality was 11% in the Co-trimoxazole group vs 29% in the standard therapy group (p=0.020). Mechanical ventilation was offered to 9% of the patients in the Co-trimoxazole group versus 13% of the patients in the standard therapy group. Time to recovery was 6 days in the Co-trimoxazole group versus 7 days in the standard therapy group (p=0.466). Conclusion(s): In this interim analysis oral Co-trimoxazole reduces mortality in patients with severe Covid-19. Further recruitment is underway.

3.
Journal of the Indian Chemical Society ; 98(10):11, 2021.
Article in English | Web of Science | ID: covidwho-1510018

ABSTRACT

COVID-19 is considered as a major public health problem caused by the SARS CoV-2. This Viral infection is known to induce worldwide pandemic in short period of time. Emerging evidence suggested that the transmission control and drug therapy may influence the preventive measures extensively as the host surrounding environment and pathogenic mechanism may contribute to the pandemic condition earlier in COVID-19 disease. Although, several animals identified as reservoir to date, however human-to-human transmission is well documented. Human beings are sustaining the virus in the communities and act as an amplifier of the virus. Human activities i.e., living with the patient, touching patient waste etc. in the surrounding of active patients or asymptomatic persons cause significant risk factors for transmission. On the other hand, drug target and mechanism to destroy the virus or virus inhibition depends on diversified approaches of drugs and different target for virus life cycle. This article describes the sustainable chemical preventive models understanding, requirements, technology adaptation and the implementation strategies in these pandemic-like situations. As the outbreak progresses, healthcare models focused on transmission control through disinfections and sanitization based on risk calculations. Identification of the most suitable target of drugs and regional control model of transmission are of high priority. In the early stages of an outbreak, availability of epidemiological information is important to encourage preventive measures efforts by public health authorities and provide robust evidence to guide interventions. Here, we have discussed the level of adaptations in technology that research professionals display toward their public health preventive models. We should compile a representative data set of adaptations that humans can consider for transmission control and adopt for viruses and their hosts. Overall, there are many aspects of the chemical science and technology in virus preventive measures. Herein, the most recent advances in this context are discussed, and the possible reasons behind the sustainable preventive model are presented. This kind of sustainable preventive model having adaptation and implementation with green chemistry system will reduce the shedding of the virus into the community by eco-friendly methods, and thus the risk of transmission and infection progression can be mitigated.

4.
Journal of Association of Physicians of India ; 69(11):14-16, 2021.
Article in English | Scopus | ID: covidwho-1507498

ABSTRACT

Background: Chemoprophylaxis (CP) along with masking and physical distancing seem an undeniable alternative. Considering the significant but uncertain role of CP for the current COVID-19 pandemic situation, we aimed to determine the various aspects of CP prescribing practices among physicians across India. Methods: An online survey was conducted among prescribing physicians across India where physicians were assessed for their prescribing practices on COVID-19 CP. Responses to the questionnaire were obtained via telephone, email and WhatsApp messages. Responses were duly analyzed thereafter. Result: Ivermectin was the preffered choice in 44% individuals followed by hydroxychloroquine in 34% individuals. Odds of COVID contact among those using HCQ and/or IVR prophylaxis was less than 1 of which IVR was found more protective. The present study also made a survey among 309 community dwellers, where odds of contacted COVID among those with any prophylaxis was 0.46 times than those without any prophylaxis. Conclusion: The HCPs found IVR to have a greater risk reduction than with HCQ;while the combination showed the greatest reduction and lack of CP use was associated with a high risk of SARS-CoV-2 infection. © 2021 Journal of Association of Physicians of India. All rights reserved.

5.
The Journal of the Association of Physicians of India ; 69(7):11-12, 2021.
Article in English | Scopus | ID: covidwho-1431386

ABSTRACT

BACKGROUND: Since its first identification in December 2019, in WUHAN (CHINA), SARS-COV-2, causative agent of Corona virus pandemic, has affected millions of people worldwide, causing thousands of death. There is much speculation about the interplay between ACEI/ARB and Corona virus infection, as for internalization into host cell SARS-COV-2 binds through S spike protein to ACE-2, aided TMPRSS2. METHODS: A record based observational study has been conducted (data obtained from the clinics of fourteen physicians) in two worst affected districts of West Bengal, to find out the association of ACEI/ARB on patients, suffering from Corona virus infection. The study-protocol has already been approved by Clinical Research Ethics Committee of Calcutta School of Tropical Medicine. (IEC Ref. No: CREC-STM/2020-AS-37) Results: Increasing age, male sex and presence of co-morbidities (viz. Diabetes, COPD) are significantly associated with the occurrence of moderate and severe disease. Drugs (viz. ACEI/ARB), though are associated with less severe disease, have not achieved statistical significance, in the present study. CONCLUSION: Drugs, like ACEI/ARB, should be continued in patients suffering from COVID-19 infection, (if they are already on these drugs). © Journal of the Association of Physicians of India 2011.

6.
Journal of the Indian Medical Association ; 118(10):86-89, 2020.
Article in English | Scopus | ID: covidwho-1426851

ABSTRACT

Age old anthelmintic drug ivermectin Is showing some promises In the management of COVID 19 patients. In vitro study suggests anti SARS CoV2 viral role of ivermectin but there is some controversy regarding dose selection. Ivermectin has immunomodulatory roie which may be responsible for Its beneficial effects. Though it Is not included in interim COVID 19 management guideline by GOt, but several states like West Bengal, Bihar, UP, Assam have included it in state COVID 19 management guideline. It Is important to be vigilant and more focused to prospectlvely observe the outcome in COVID 19 patients. © 2020, Indian Medical Association. All rights reserved.

7.
Journal of Association of Physicians of India ; 69(7):28-33, 2021.
Article in English | Scopus | ID: covidwho-1361002

ABSTRACT

Background: Since its first identification in December 2019, in WUHAN (CHINA), SARS-COV-2, causative agent of Corona virus pandemic, has affected millions of people worldwide, causing thousands of death. There is much speculation about the interplay between ACEI/ARB and Corona virus infection, as for internalization into host cell SARS-COV-2 binds through S spike protein to ACE-2, aided TMPRSS2. Methods: A record based observational study has been conducted (data obtained from the clinics of fourteen physicians) in two worst affected districts of West Bengal, to find out the association of ACEI/ARB on patients, suffering from Corona virus infection. The study-protocol has already been approved by Clinical Research Ethics Committee of Calcutta School of Tropical Medicine. (IEC Ref. No: CREC-STM/2020-AS-37) Results: Increasing age, male sex and presence of co-morbidities (viz. Diabetes, COPD) are significantly associated with the occurrence of moderate and severe disease. Drugs (viz. ACEI/ARB), though are associated with less severe disease, have not achieved statistical significance, in the present study. Conclusion: Drugs, like ACEI/ARB, should be continued in patients suffering from COVID-19 infection, (if they are already on these drugs). © 2021 Journal of Association of Physicians of India. All rights reserved.

8.
Journal of the Indian Medical Association ; 119(4):50-54, 2021.
Article in English | EMBASE | ID: covidwho-1357945

ABSTRACT

The COVID-19 pandemic which started in late 2019 is still continuing unabated, rather with resurgence of cases in certain areas globally. Even with the emergency use authorization of several vaccines and extensive vaccination programs, we are yet to bring the pandemic to its knees. The present scenario has more than ever highlighted the importance of face masks in controlling the infection and transmission of the SARS CoV2 virus. In this review article, we discuss the evidence available to date to support the use of masks as a protective barrier to limitvirus entry. We also discuss how masks indirectly help stimulate protective immune responses and provide a comparative glimpse on the characteristics of various masks.

9.
Journal of Indian Medical Association ; 118(5):72, 2020.
Article in English | EMBASE | ID: covidwho-832282
10.
Journal of the Indian Medical Association ; 118(8):74-75, 2020.
Article in English | EMBASE | ID: covidwho-740732
11.
Journal of the Indian Medical Association ; 118(6):85, 2020.
Article in English | EMBASE | ID: covidwho-681540
12.
Journal of the Indian Medical Association ; 118(6):79-81, 2020.
Article in English | EMBASE | ID: covidwho-678617

ABSTRACT

Remdesivir currently is the only recognized specific therapy, though with emergency use authorization (EUA), in Covid-19. The Ministry of Health &Family Welfare, Government of India has included it as a possible 'newer therapy' as Compassionate Emergency use under Named Patient Basis on June 13, 2020 and is being perceived as a ray of hope in Moderate to Severe Covid-19 cases.

SELECTION OF CITATIONS
SEARCH DETAIL